The Inhibition of NLRP3 Inflammasome and IL-6 Production by Hibiscus noldeae Baker f. Derived Constituents Provides a Link to Its Anti-Inflammatory Therapeutic Potentials by Tomani, Jean Claude Didelot et al.
  
Molecules 2020, 25, 4693; doi:10.3390/molecules25204693 www.mdpi.com/journal/molecules 
Article 
The Inhibition of NLRP3 Inflammasome and IL-6 
Production by Hibiscus noldeae Baker f. Derived 
Constituents Provides a Link to Its Anti-
Inflammatory Therapeutic Potentials 
Jean Claude Didelot Tomani 1,2, Vedaste Kagisha 1,3, Alembert Tiabou Tchinda 4, Olivia Jansen 3, 
Allison Ledoux 3, Luc Vanhamme 2, Michel Frederich 3,†, Raymond Muganga 1,†  
and Jacob Souopgui 2,*,† 
1 School of Medicine and Pharmacy, College of Medicine and Health Sciences, University of Rwanda,  
P.O. Box 3286, Kigali, Rwanda; Jean.Claude.Tomani@ulb.ac.be (J.C.D.T.);  
kagishavedaste@gmail.com (V.K.); rmuganga@yahoo.fr (R.M.) 
2 Department of Molecular Biology, Institute for Molecular Biology and Medicine, Université Libre de 
Bruxelles, 6041 Gosselies, Belgium; Luc.Vanhamme@ulb.ac.be 
3 Laboratory of Pharmacognosy, Centre for Interdisciplinary Research on Medicines (CIRM),  
University of Liège, B36, 4000 Liège, Belgium; ojansen@ulg.ac.be (O.J.); allison.ledoux@ulg.ac.be (A.L.); 
M.Frederich@uliege.be (M.F.) 
4 Laboratory of Phytochemistry, Centre for Research on Medicinal Plants and Traditional Medicine,  
Institute of Medical Research and Medicinal Plants Studies, P.O. Box 6163, Yaoundé, Cameroon; 
talembert@gmail.com 
* Correspondence: jsouopgu@ulb.ac.be; Tel.: +32-2-650-9936 
† These authors contributed equally to this work. 
Academic Editor: Massimo Bertinaria 
Received: 6 September 2020; Accepted: 12 October 2020; Published: 14 October 2020 
Abstract: The activation of NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) 
inflammasome and/or its components is associated with the physio-pathogenesis of many 
respiratory diseases including asthma, COPD (chronic obstructive pulmonary disease), SARS Cov-
2 (severe acute respiratory syndrome coronavirus 2), and in several autoimmune diseases. Hibiscus 
noldeae Baker f. has been widely reported to be traditionally used in the treatment of different 
ailments, some of which are of inflammatory background such as asthma, wounds, headache, etc. 
However, the claims have not been supported by evidence at the molecular and functional levels. 
Here, we report on the bio-guided fractionation of H. noldeae and assessment of the inhibitory 
properties of some fractions and purified compounds on NLRP3 inflammasome and Interleukin 6 
(IL-6). The activation of the NLRP3 inflammasome was determined by detecting the activity of 
caspase-1 and the production of Interleukin 1β (IL-1β) in Lipopolysaccharide (LPS) and ATP-
stimulated Tamm-Horsfall Protein 1 (THP-1) macrophages, while the production of IL-6 was 
studied in LPS-stimulated RAW264.7 mouse macrophages. It was observed that hexane and ethyl 
acetate fractions of the crude extract of the aerial parts of H. noldeae, as well as caffeic acid, 
isoquercetin, and ER2.4 and ER2.7 fractions revealed significant inhibitory effects on Caspase-1 
activities, and on IL-1β and IL-6 production. The ER2.4 and ER2.7 fractions downregulated the 
production of IL-1β and IL-6, in a similar range as the caspase-1 inhibitor AC-YVAD-CHO and the 
drug Dexamethasone, both used as controls, respectively. Overall, our work does provide the very 
first scientific based evidence for Hibiscus noldeae anti-inflammatory effects and widespread use by 
traditional healers in Rwanda for a variety of ailments. 
  
Molecules 2020, 25, 4693 2 of 16 
 




Respiratory diseases, with asthma being the most important, are classified among the major 
categories of non-communicable diseases and their prevalence accounted for more than 1 billion 
patients worldwide in 2018 [1,2]. Asthma is a chronic inflammatory disease resulting from the 
malfunction of the interaction between the airways and the immune cells [3,4]. Inflammation is 
considered to be a physiological defense mechanism which helps the body to protect itself from 
microbial infections, burn, toxic chemicals, allergens, or other harmful stimuli. Depending on the 
number or the degree of events and mediators linked to that reaction, inflammatory reaction can 
trigger, maintain, or aggravate many diseases [5]. Sometimes the delicate balance between immune-
mediated clearance and noxious stimuli is troubled and this correlates with inadvertent self-harm 
from chronic inflammation. As a result, the immune system inappropriately leads to inflammation 
against its own cells, resulting in different chronic inflammatory diseases including respiratory 
diseases such as asthma and chronic obstructive pulmonary disease (COPD) [6]. Recently, the 
complicated form of SARS Cov-2 (severe acute respiratory syndrome coronavirus 2) viral pneumonia 
outbreak was reported to be associated with a plethora of cytokines wreaking havoc throughout the 
body often vividly referred to as “cytokine storm”, which triggers a violent inflammatory immune 
response that contributes to respiratory problems, multiple organ failure, and finally death in severe 
cases of SARS-CoV-2 infection [7–10]. Several studies have reported the role of different 
inflammatory cells and mediators in the pathogenesis of asthma where the volume and nature of 
involved inflammatory mediators determine the severity and exacerbations of the disease. 
Depending on those inflammatory patterns, there are two main subtypes of asthma, the eosinophilic 
(diagnosed by the expression of Th2-derived cytokines) and the neutrophilic (diagnosed by the 
expression of Th17-derived cytokines and chemokines) [11]. The latter asthma subset is characterized 
by a high proportion of neutrophils recruited by inflammatory cytokines like Interleukin 1β (IL-1β), 
Interleukin 6 (IL-6), and Tumor Necrosis Factor Alpha (TNF-α). It is well known that inflammasomes, 
multiprotein cytoplasmic complexes activating inflammatory responses, are involved in the 
upregulation of these cytokines, particularly the IL-1β through the activation of caspase-1 [12,13]. 
Among these inflammasomes, NOD-, LRR-, and pyrin domain-containing protein 3 (NLRP3) is the 
most widely studied and its properties and functions are the best characterized [14]. In fact, in 
response to a microbial infection or injury, the NLRP3 inflammasome is activated and involved in 
the host protection by inducing immune responses to clear injury or microbial invasion [13,14]. The 
activation of NLRP3 inflammasome requires two distinct signals. The first is a pro-inflammatory 
priming step, mediated by toll-like receptors (TLR), that induces the upregulation of the NF-κB 
transcription factor and promotes the expression of pro-IL-1β and the NLRP3 inflammasome 
component. The second signal is an activation step that induces the assembly of the NLRP3/ 
Apoptosis-associated speck-like protein containing a caspase recruitment domain (ASC)/pro-
caspase-1 complex, ending up in the proximity auto-cleavage and maturation of caspase-1 which, in 
turn, induces a caspase-1-mediated maturation of pro-IL-1β and release of active IL-1β [15]. Several 
pieces of evidence from research suggest that inflammasomes and/or their components and effectors 
are associated with the physio-pathogenesis of asthma and other respiratory diseases including 
COPD, SARS CoV-2, etc. [15–18]. In fact, it has been reported that the excessive release of active IL-
1β and ASC (apoptosis-associated speck-like protein containing a caspase recruitment domain) 
specks leads to the induction of neutrophil-dominated inflammatory responses in the airways that 
contributes to the pathogenesis of COPD and neutrophilic asthma [16,17]. 
The neutrophilic asthma is the most severe and has been reported to be refractory to the 
corticoid-based treatment [16]. Despite this resistance, the use of corticosteroids remains the basic 
treatment for several respiratory diseases involving cytokine storms. A recent clinical trial report 
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revealed that the treatment with Dexamethasone significantly alleviated COVID-19 disease severity 
of hospitalized patients who were under invasive mechanical ventilation or oxygen [19]. Regarding 
the neutrophilic asthma, drugs that alleviate disease severity include specific monoclonal antibodies 
against key mediators of the inflammatory pathway [20] but the associated treatment cost is not 
affordable for low and middle income countries (LMICs). Hence, urgent efforts are needed to identify 
new, effective, affordable, and safe anti-inflammatory drugs. A reliable therapeutic source which 
remains poorly explored is the traditional pharmacopeia. Previously, our investigations on the anti-
asthmatic activities of herbal recipes from Rwandese traditional healers revealed a candidate recipe 
with significant inhibitory properties on the activation of caspase-1 using Caspase-Glo 1 
Inflammasome assays [21]. Hibiscus noldeae, from the Hibiscus genus in the Malvaceae family, was one 
of the plants composing the recipe. Plants from the same Hibiscus genus, including H. acetosella, H. 
sabdariffa, and H. vitifolius have been reported to have anti-inflammatory potentials and some of the 
responsible molecules, such as gossypin, caffeoylhydroxycitric acid, delphinidin-3-sambubioside, 
and neochlorogenic acid have been isolated [22–24]. In contrast, no such studies has been reported 
on H. noldeae, although used by traditional healers in the treatment of asthma, urogenital infections, 
postpartum abdominal pain, swelling of the legs, cleaning of babies, facilitation of delivery, sprains, 
headache, wounds, women infertility, abortion prevention, etc. [21]. 
In this study, we report on the bio-guided fractionation of H. noldeae and assessment of the 
inhibitory properties of some fractions and purified compounds on NLRP3 inflammasome and IL-6. 
The activation of the NLRP3 inflammasome was determined by detecting the activity of caspase-1 
and the production of IL-1β in Lipopolysaccharide (LPS)- and ATP-stimulated THP-1 macrophages, 
while the production of IL-6 was studied in LPS-stimulated RAW264.7 mouse macrophages, a well-
known standard method. It was observed that hexane and ethyl acetate fractions of the aerial parts 
of H. noldeae, as well as caffeic acid, isoquercetin, and ER2.4 and ER2.7 fractions revealed the highest 
inhibitory effects on Caspase-1 activities, and on IL-1β and IL-6 production. The ER2.4 and ER2.7, our 
fractions of most interest, downregulated the production of IL-1β and IL-6, in a similar range as the 
caspase-1 inhibitor AC-YVAD-CHO and the drug Dexamethasone all used as controls, respectively. 
Overall, our findings pave the way for the first time on the scientific based evidence on Hibiscus 
noldeae activities underlying its potential role in the treatment of inflammatory diseases and asthma 
in Rwanda. 
2. Results 
Hibiscus noldeae (H. noldeae) has been studied by virtue of its attribute as one of the medicinal 
plants used by the traditional healers in Rwanda to manufacture their remedies. In the context of 
asthma treatment, the recipe, containing 7 different plants, that revealed the best anti-inflammatory 
activity [21] comprised H. noldeae in major proportion (35%). We therefore hypothesized that this 
medicinal plant may harbor the therapeutic constituents. 
2.1. Hexane and Ethyl Acetate Fractions Revealed Similar HPLC Profiles for the Constituents of the Crude 
Extract of the Aerial Parts of H. noldeae 
A bio-guided fractionation approach was employed and as shown in Figure 1, a complex 
chemical profile for hexane and ethylacetate fractions was observed in the High performance Liquid 
Chromatography with Diode-Array Detection (HPLC-DAD) analysis, indicating the presence of 
different major substances of different polarities. Many peaks eluted between 20 and 40 min, a fact 
that demonstrates the presence of medium polarity molecules, most of which are major compounds. 
The transposition of the analytical method to the preparative HPLC allowed for the isolation of five 
of the seven major compounds from ethylacetate and hexane fractions of H. noldeae. Three of the five 
isolated compounds were pure and were identified by chromatographic and/or spectroscopic 
comparison with data from literature. This led to the elucidation of one flavone glycoside, namely 
quercetin 3-O-glucopyranoside, along with two polyphenols, caffeic acid and caffeoyl-hydrocitric 
acid (Supplementary Table S1 and Figures S1–S3). 
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Figure 1. High performance Liquid Chromatography (HPLC) Chromatograms of the hexane (Hex) 
and ethylacetate (EtoAc) fractions of H. noldeae. An in-house HPLC method used to screen the major 
components of crude extract was used. Analytical separation was carried out on a Hypersil ODS®  
RP18 column (250 × 4.6 µm; particle size 5 µm; Thermofisher Scientific, Waltham, MA, USA). All 
samples were dissolved in methanol HPLC-grade, filtered through a 0.45 μm pore size filter 
membrane and analyzed on an Agilent 1100 HPLC machine. Samples were eluted with a nonlinear 
gradient method with acetonitrile and 0.05% trifluoroacetic acid in ultra-pure water. The column 
temperature was maintained at 25 °C. Then 20 μL of each sample were injected into the HPLC-
UV/DAD (Diode-Array Detection) system and the analysis, performed at a flow rate of 1.0 mL/min, 
was monitored at 210, 254, 288, and 350 nm. 
2.2. Hexane and Ethyl Acetate Extracted Constituents of Hibiscus noldeae Inhibit the Activation of the 
NLRP3 Inflammasome in THP-1 Macrophages 
Prior to the investigation of anti-inflammatory properties of the compounds of interest, their 
effect on the cell viability on both THP-1 monocytes and derived macrophages was first determined. 
Cells were treated with different concentrations (0, 25, 50, and 100 µg/mL) for 24 h, and the cell 
viability was determined using CellTiter-Glo Luminescent Cell Viability Assay kit (Promega Co., 
Madison, WI, USA). Up to 25 µg/mL, all tested compounds did not exhibit cytotoxicity to both THP-
1 and RAW264.7 cell lines (Figures S4 and S5). Our anti-inflammatory activities were therefore 
determined within this range. 
To investigate whether the isolated compounds and fractions of interest possessed potential 
NLRP3 inflammasome inhibitory effects, their influence on the NLRP3 inflammasome activation, in 
LPS and ATP-stimulated THP-1-derived macrophages was assessed. The levels of caspase-1 activities 
in the culture media were determined using the Caspase-Glo®  1 Inflammasome Assay (Promega Co., 
Madison, WI, USA). As shown in Figure 2 below, it was observed as expected that LPS and ATP 
treatment significantly (*** p < 0.0001) increased caspase-1 activities in the cell culture supernatant 
when compared with the untreated cells. However, when cells were pretreated with the isolated 
compounds and fractions of interest in graded concentrations ranging from 5 to 20 µg/mL, the 
caspase-1 activities were reduced by at least 34%. The tested compounds revealed their maximal 
inhibitory activities at 5 µg/mL, except for the ER2.4 fraction that showed a dose-dependent inhibition 
of the caspase-1 activation (Figure 2). 
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Figure 2. Crude extract (a) and Hexane (c) and ethylacetate (b) fractions as well as the caffeic acid (f) 
and semi-purified fractions, ER 2.4 (d) and ER 2.7 (e), thereof exhibited significant inhibition of 
caspase-1 in THP-1 derived macrophages. Phorbol Myristate Acetate (PMA)-differentiated cells were 
pretreated by corresponding compounds for 1 h, and then primed by Lipopolysaccharide (LPS) (1 
µg/mL) for 3 h. Cells were then stimulated by ATP (5 mM) for additional 1 h. The supernatants were 
harvested and kept at −70 °C before analysis. Then, 50 µL of the culture supernatant were used to 
determine the caspase-1 activity using Caspase-Glo 1 inflammasome assay (Promega Co., Madison, 
WI, USA). The results are presented as the mean ± SD from independent experiments (n = 2), each 
done in triplicate. A one-way ANOVA, followed by Benforroni’s multiple comparison test, was used 
to compare the sample groups. *** means Caspase-1 fold activation changes with a p < 0.0001. 
Next, the production of IL-1β was investigated using the human IL-1β (enzyme linked 
immunosorbent assay) ELISA kit (Invitrogen/Thermofisher, Waltham, MA, USA). As controls, two 
distinct reference inhibitors, namely Ac-YVAD-CHO (YVAD) which specifically acts on caspase 1 
and Dexamethasone (Dex) which downregulates the NF-κB pathway were used. As results, it was 
observed as expected that LPS and ATP treatment significantly (*** p < 0.0001) increased the 
production of IL-1β in the cell culture supernatant when compared with the untreated cells (Figure 
3A). When cells were first treated with H. noldeae constituents or the controls, the production IL-1β 
was significantly inhibited. Reductions of more than 70% could be revealed in some cases (Figure 
3A). Moreover, it was observed that, at equivalent dose of 20 µg/mL, ER2.7 fraction and 
Dexamethasone showed similar inhibitory effects, while at the same concentration other tested 
constituents of H. noldeae revealed inhibitory activities comparable to the caspase 1 reference inhibitor 
YVAD. Isoquercetin was observed to have the lowest inhibitory effect on IL-1β production (Figure 
3A). 




Figure 3. Inhibition of IL-1β production by H. noldeae constituents. (A) PMA-differentiated cells were 
pretreated with the indicated plant constituents at the concentration range shown for 1 h, and then 
primed by LPS (1 µg/mL) for 3 h. Concentrations of 20 µM YVAD and 20 µg/mL Dex were used as 
controls. Cells were then stimulated by ATP (5 mM) for additional 1 h. Supernatants were harvested 
and kept at −70 °C before analysis. For the ELISA analysis, samples were diluted 10 times in the assay 
diluent. The concentration of IL-1β in the culture supernatant was measured using a human IL-1β 
Enzyme linked immunosorbent assay (ELISA) kit (Invitrogen/Thermofisher, Waltham, MA, USA) 
according to the manufacturer’s instructions. For each experiment, the amount of IL-1β produced 
without any pretreatment was considered as 100% and the remaining treatments were calculated as 
(Treatment/LPS) × 100. The results are presented as the mean ± SD of a triplicate from a representative 
of three independent experiments (n = 3). A one-way ANOVA, followed by Benforroni’s multiple 
comparison test, was used to compare the sample groups. *** stands for p < 0.0001. (B) 
Immunoblotting of cell lysates by anti-ProIL-1β (Cell signaling Technology, Danvers, MA, USA) or 
anti-Pro caspase-1 (Abcam, Cambridge, UK) was done twice according to the manufacturer’s 
instructions. Membranes were then stripped, reprobed with anti-β-Actin antibodies and exposed 
again to detect the internal β-Actin standard. 
It is well-known that the activation of the NLRP3 inflammasome induces the activation of 
caspase-1 that promotes the production of Gasdermin D. The N-terminal domain of Gasdermin D 
oligomerizes to form cytolytic pores and leads to the programmed cell death called “pyroptosis” [25]. 
Therefore, we investigated the effect of our compounds and fractions of interest on inflammasome 
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activation-induced cell death by measuring the release of lactate dehydrogenase (LDH) in the culture 
supernatants. As expected, the pretreatment of cells by our test compounds significantly inhibited 
ATP-induced pyroptosis (Figure S6). 
NLRP3 inflammasome-associated IL-1β production is a two-step process: a priming signal that 
promotes Pro-IL-1β and NLRP3 synthesis and a secondary signal that induces the inflammasome 
assembly and the subsequent caspase-1 activation [26]. We investigated the effect of the crude extract 
and fractions of interest on the expression of Pro-IL-1β and Pro-Caspase-1 by Western blot (WB). We 
observed as shown in Figure 3B that cells pretreatment with ER2.4 and ER2.7 fractions led to the 
reduced Pro-Caspase-1 amount marked by the faint WB-signals. This suggest that our fractions of 
interest inhibited the expression of this protein by impacting the first priming step of the NLRP3 
inflammasome activation or induced its degradation by a mechanism to be clarified. Moreover, the 
Pro-IL-1β production appeared induced as marked by the width of the WB-signals (Figure 3B). 
Knowing the critical role of Caspase-1 in the inflammasome activation, these observations suggest 
that the reduced expression of the Pro-Caspase by both ER2.4 and ER2.7 fractions may in fact be 
acting to inhibit the upregulation of Caspase-1, hence block the Pro-IL-1β cleavage. In addition, 
treatment with Dexamethasone, the crude extract and the EtoAc fraction revealed reduced Pro-IL-1β 
WB-signals. While the effect of Dexamethasone is associated with the inhibition of the NF-κB 
activities leading to the repression of Pro-IL-1B production, the effects of the crude extract and EtoAc 
fraction could results from the dilution of the ER2.4 and ER2.7 fractions or likely their effects on NF-
kB activities by their constituents to be identified. 
2.3. Hexane and Ethyl Acetate Fractions and Purified Compounds from H. noldeae Inhibit IL-6 Production 
Interleukin 6 (IL-6) like IL-1β is a biomarker of inflammasome activation. Hence, the effect of the 
fractions and purified compounds from H. noldeae on the production of IL-6 in RAW264.7 
macrophages supernatants by ELISA was investigated. Dexamethasone at concentration of 20 µg/mL 
was used as control. Treatment of RAW264.7 cells with LPS alone resulted in a significant increase in 
this cytokine production as compared to the control group. As expected, a pre-treatment of cells with 
Dexamethasone reduced about 72% of the production of IL-6. Also, it was observed that the levels of 
IL-6 production were significantly (*** p < 0.0001) decreased upon pre-treatment of cells with H. 
noldeae constitutuents. Moreover, while a saturation of inhibitory effects was already observed at 
either 5 or 10 µg/mL with the ER2.4 fraction or with the crude extract and the EtoAc fraction, a dose-
dependent inhibition of IL-6 production was revealed by the caffeic acid and ER2.7 fraction pre-
treatment. At 20 µg/mL, the inhibitory effect of ER2.7 fraction was similar to that of Dexamethasone 
(Figure 4). 
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Figure 4. Inhibition of IL-6 production by H. noldeae constituents. Cells were pre-treated with crude 
extract (a), EtoAc fraction (b) and partially purified ER 2.4 (d) and ER 2.7 (e) fractions, and caffeic acid 
(c) for 3 h and stimulated by LPS (1 µg/mL) for 18 h. Dexamethasone (Dex) at 20 µg/mL was used as 
a control. Cell-free supernatants were harvested and stored at −70 °C until analysis. The concentration 
of IL-6 in the culture supernatant was measured using IL-6 ELISA kit (BD Biosciences) according to 
the manufacturer’s instructions. For each experiment, the amount of IL-6 produced was considered 
as 100% and the remaining treatments was calculated as (Treatment/LPS) × 100. The results are 
presented as the mean ± SD from a triplicate of the representative experiment. A one-way ANOVA, 
followed by Benforroni’s multiple comparison test, was used to compare the sample groups. *** 
stands for a p < 0.0001. 
3. Discussion 
An important body of studies have proven the associations between neutrophilic asthma and 
increased IL-1β responses induced by the excessive NLRP3 inflammasome activation. This raises the 
possibility of targeting different inflammasome components as substantial therapeutic targets in 
neutrophil-dominated forms of severe, steroid-refractory asthma [16]. The analysis of inflammasome 
formation is mostly investigated through the monitoring of downstream processes and outcomes, 
the presence of cleaved caspase-1 enzyme being the most widely used method, as well as the caspase-
1 activity on substrates such as pro-IL-1β, pro-IL-18, and pro-gasdermin-D [14]. In view of 
determining the inhibitory properties of the H. noldeae constituents of interest on NLRP3 
inflammasome, their effect on either caspase-1 activation using the Caspase Glo 1 assays (Promega, 
Madison, WI, USA) and/or IL-1β production as hallmarks of the NLRP3 inflammasome was 
evaluated. In fact, it is well known that the inflammasome activation induces a cascade of events 
including the recruitment of pro-caspase-1 and its cleavage into a corresponding active caspase-1 
enzyme that also cleaves pro-IL-1β into its mature form, IL-1β [14]. 
In our previous study, among the plant recipes evaluated, R19Sz was the most potent in 
inhibiting caspase-1 activity [21]. Hibiscus noldeae, one of the plant’s components of the recipe, has 
been cited by three different traditional healers during our investigation, indicating its possible 
importance in the treatment of asthma. In addition, few studies reported on the traditional use of the 
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plant in the treatment of different ailments, some of which are of inflammatory background such as 
asthma, wounds, headache, etc. [21,27,28,29]. An important question was then to determine whether 
H. noldeae, would have inhibitory properties on inflammasome or on IL-6 production, a well-known 
downstream target of IL-1β. A bioguided fractionation approach to address this question was 
employed. Many of the isolated compounds (Figure 1 and Table S1) were polyphenols, secondary 
plant metabolites proven to exert various biological properties including anti-bacterial, anti-
inflammatory and anti-allergic activities [30,31,32]. As far as inflammation is concerned, cell death 
could also lead to the activation of the inflammatory pathway in a manner similar to the 
inflammasome activation [33,34]. Therefore, plant crude extracts, fractions and purified compouds 
were first tested for eventual cytotoxicity allowing to select the range of working sample 
concentrations in such a way that their pharmacological effects could not be biased. 
Within a plant extract, there can be hundreds of molecules, some of which are active individually 
or act synergistically against a given disease. In most of the cases, major compounds are responsible 
of the activity of the extract though it is not always the case [35,36]. In this study, an important 
question was to determine whether the inhibition of NLRP3 inflammasome resulted from a single 
compound or from a combined effect of different compounds. We opted first to investigate the effect 
of cell pre-treatment with our various samples on the caspase-1 activities and observed an average 
reduction of about one-third which formed a plateau at the tested concentration ranges as shown in 
(Figure 2). Such reduction suggested the presence of an inhibitor of caspase-1 in the plant extract. 
Indeed, caffeic acid, purified from H. noldeae in this work, was reported to interact with and inhibits 
Caspase-1 and ASC activation [36]. The plateau could be explained by the fact that a saturated 
quantity of caffeic acid is already in the lowest sample concentration used (5 µg/mL). 
The findings that our plant products of interest had inhibitory effects on the caspase-1 activities 
prompted us to assess the production of IL-1β in the supernatant from the different samples. 
Consistent with the inhibition of the caspase-1 activities all the tested crude extract, fractions and 
purified constituents of H. noldeae revealed significant inhibition of IL-1β production (Figure 3A). To 
ensure that H. noldeae constituents acted on the inflammasome activation pathway, we further 
investigated their effects on pyroptosis. In fact, the activation of the NLRP3 inflammasome induces 
the activation of caspase-1 that promotes the production of Gasdermin D and the latter is associated 
to the programmed cell death called “pyroptosis” [25]. In contrast, compared to the production of IL-
1β, the effect of Dexamethasone was less than that of ER2.4 and ER2.7 fractions (Figure S6). This may 
be explained by the fact that Dexamethasone is able to act at the transcriptional level or to selectively 
induce the degradation of IL-1β transcripts after their production [37]. Thus, the additional effect of 
these both mechanisms justifies its enhanced inhibition of IL-1β production in the supernatant. 
However, at the highest concentration tested (20 µg/mL) an unexplained ease of the inhibitory effect 
was observed with both fractions. Such unexpected reactions deserve further investigation during 
the characterization of ER2.4 and ER2.7 fractions.  
NLRP3 inflammasome-associated IL-1β production is a two-step process. Our findings on both 
pyroptosis assays (Figure S6) and IL-1β production (Figure 3A) suggest that H. noldeae derived 
products interfere with the NLRP3 inflammasome signaling, to block cell death (pyroptosis) and IL-
1β production. However, the Western blot results showed that ER2.4 and ER2.7 fractions repressed 
the expression of Pro-Caspase-1 (Figure 3B). Capsase-1 is a critical component of the inflammasome 
and the reduced expression of this enzyme by fractions from H. noldeae indicates that ER2.4 and ER2.7 
may in fact be acting to inhibit signal 1 (priming step) of inflammasome activation by specifically 
blocking upregulation of Caspase-1. In our future research, the mode of action of the molecules 
contained in these fractions will be elucidated. 
Several studies have reported in vivo anti-inflammatory properties of caffeic acid and 
isoquercetin as well as several corresponding derivatives [36,38,39]. In this study, as suggested by 
our results, several polyphenolic compounds detected in the plant extracts of H. noldeae likely 
contribute to the inhibitory property of the plant on the inflammasome expression. However, the 
activity of the plant remains inferior to the activity of purified caffeic acid as well as the concentrated 
fractions ER2.4 and ER 2.7. This suggests that the fractionation of the plant extracts led to the 
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enhancement of their inflammasome inhibition potency. This is in accordance with previous studies 
that reported the beneficial effect of fractionation in concentrating polyphenolic compounds, leading 
to enhanced biological activities [40,41]. We thus argue that the bioactive compounds in fraction 
ER2.4, ER2.7 together with the well-known caffeic acid and isoquercetin are the main compounds 
involved in the regulation of the NLRP3 inflammasome. 
In the present study, the effect of our plant samples on the production of IL-6 in RAW264.7, a 
murine cell line widely used for the in vitro production of IL-6, was also investigated. This cytokine 
is a known downstream target of IL-1β and is consistently increased in serum from patients with 
NLRP3 inflammasome-mediated conditions. In fact, IL-1β has been reported to be one of the most 
potent activators of IL-6 production, both in vitro and in vivo, suggesting that IL-6 could be a 
therapeutic target in the treatment of IL-1β-mediated inflammation [42]. In addition, abnormal 
expression of IL-6 has been associated with the pathogenesis of a variety of human diseases, including 
asthma, cancers and autoimmune diseases such as rheumatoid arthrosis, and recently with COVID-
19 [43,44]. In asthma, it has been reported that IL-6 is linked with mixed eosinophilic–neutrophilic 
bronchitis during exacerbations of the disease and worse pulmonary function in humans [44]. 
Moreover, cytokine-targeting therapies are gaining an increasing popularity in the treatment of 
inflammatory diseases including asthma and other respiratory diseases. With the Covid-19 outbreak 
pandemic, it has been reported that dexamethasone and monoclonal antibody drugs targeting IL-6 
(tocilizumab) reduced the mortality rate [19,45,46]. In the light of the above-mentioned role of IL-6 in 
different pathologies, we investigated the effect of the H. noldeae constituents of interest on its 
production in RAW264.7 cell line. As shown in Figure 4, results obtained indicate that fractions and 
partially purified ER2.4 and ER2.7 compounds from the plant exhibited similar trends as on IL-1β 
production (Figure 3A). These findings allowed to argue that this medicinal plant is an important 
drug target for ‘cytokine storm’- related diseases such as the neutrophilic asthma and the COVID-19 
pandemic. 
4. Materials and Methods 
4.1. Collection of Plant Materials 
Aerial parts of Hibiscus noldeae were collected from the arboretum of Ruhande, in Huye district, 
Southern province in Rwanda. The plant species was identified with reference to herbarium 
specimens and various literature resources by Nshutiyayesu Samuel (from the University of Rwanda, 
Huye, Rwanda) and the authentication and ID verification by Dr. Olivier Lachenaud (from the 
Botanic Garden Meise/Meise, Belgium) as previously reported [21]. 
4.2. Isolation and Structure Elucidation of Major Compounds 
4.2.1. Crude Extract Preparation and Fractionation 
The aerial parts of H. noldeae were cleaned of dust and debris and washed gently with tap water, 
and air-dried under shade. The plant material was then pulverized with a grinder. A total amount of 
500 g of the powder was extracted with the mixture of methanol: dichloromethane (3:1) as previously 
described [21]. The dried crude extract (55 g) was triturated in distilled water and then subjected to a 
liquid-liquid partitioning process using n-hexane and ethyl acetate successively. In each case, the 
mixture to be partitioned was vigorously shaken for 10 min, rested for 20 min, and then separated in 
a separatory funnel. Each partition was conducted three times and the same fractions were combined 
and dried-up using rotary evaporator. At the end, the non-soluble part was dissolved in methanol to 
make the methanol fraction. 
4.2.2. High-Performance Liquid Chromatography (HPLC) Analysis and Purification 
Major compounds from two fractions showing the highest inhibitory activity on NLRP3 
inflammasome components, namely hexane and ethylacetate fractions, were further isolated on 
preparative HPLC. To this end, an in-house HPLC method used to screen the major components of 
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crude extracts was used. In this regard, analytical separation was carried out on a Hypersil ODS®  
RP18 column (250 × 4.6 µm; particle size 5 µm; Thermofisher Scientific, Waltham, MA, USA). All 
samples were dissolved in methanol HPLC-grade, filtered through a 0.45 μm pore size filter 
membrane and analyzed on an Agilent (Santa Clara, CA, USA) 1100 HPLC machine. Samples were 
eluted with a nonlinear gradient method with acetonitrile (solvent A) and 0.05% trifluoroacetic acid 
in ultra-pure water (solvent B) (Table 1). The column temperature was maintained at 25 °C. Then, 20 
μL of each sample was injected into the HPLC-UV/DAD system and the analysis, performed at a flow 
rate of 1.0 mL/min, was monitored at 210, 254, 288, and 350 nm.  
Table 1. Mobile phase gradient for the analytical High-Performance Liquid Chromatography (HPLC). 
Time (min) 
Mobile Phase Proportion (%) 
Solvent A Solvent B 
0.0 0.0 100 
1.0 3.0 97.0 
45.0 40.0 60.0 
55.0 40.0 60.0 
56.0 60.0 40.0 
66.0 60.0 40.0 
67.0 0.0 100 
82.0 0.0 100 
Preparative HPLC analysis was carried out on a Variant PrepStar machine. All extracts (500 mg) 
were dissolved in methanol and then diluted with water. The amount of methanol was not allowed 
to exceed 30%. Samples were filtered through a 0.45 µm filter membrane before injection. The mobile 
phase consisted of trifluoroacetic acid (TFA) 0.05% in ultrapure water (A) and acetonitrile (B). The 
Table 2 gives the gradient used to separate the major compounds identified with HPLC analytical 
method described above. This gradient was obtained by transposing the analytical HPLC methods 
to preparative HPLC using HPLC calculator. The flow rate was 15 mL/min and the separation was 
monitored at 254 and 350 nm. Structural identification of isolated compounds was performed by 1D 
and 2D Nuclear Magnetic Resonance (NMR) and infrared spectroscopy (IR). The detection was 
followed at 254 and 350 nm. 
Table 2. Gradient system used to isolate compounds on preparative HPLC. 
Time (min) 
Mobile Phase Proportion (%) 
Solvent A Solvent B 
0.0 0.0 100 
2.0 3.0 97.0 
35.0 15.5 84.5 
55.0 19.0 81.0 
76.0 27.5 72.5 
98.0 31.5 68.5 
133.0 60.0 40.0 
144.0 60.0 40.0 
4.3. Cell Culture and Viability Assay 
Human leukemia THP-1 monocyte and RAW264.7 murine cell lines were kindly received from 
the Institute for Medical Immunology/BioPark/ULB and were cultured in RPMI 1640 (Life 
Technologies, Waltham, MA, USA) and DMEM, respectively. All media were supplemented with 
10% heat-inactivated Fetal Bovine Serum (FBS; Life technologies), 1% glutamine, and 1% of penicillin-
streptomycin (Life technologies) and 1% Sodium pyruvate (for RAW264.7 only) and maintained at 
37 °C under 5% CO2 in a humidified atmosphere. Cells were passaged at least 5 times before any 
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experiment. For the determination of cell densities, the cell counting was done using a Neubauer 
counting chamber with trypan blue (0.4% in PBS; pH = 7.4; Life technologies) staining. Before 
investigating the anti-inflammatory activity of different fractions, their effect on the cell viability 
(THP-1, monocytes and derived-macrophages, and RAW264.7) was screened as previously reported 
[21]. 
4.4. Caspase-1 Inhibition Assays 
The evaluation of caspase-1 activity was done using the Caspase Glo 1 inflammasome assay 
(Promega Co. Madison, WI, USA). Briefly, THP-1 cells were grown for 2 days in 24-well plates to a 
density of 2 × 105 cells/well in the presence of 10 nM PMA at 37 °C in a humidified 5% CO2 incubator. 
PMA-supplemented medium was then discarded and macrophages were pretreated with fresh 
medium containing fractions at different concentrations for 1 h. Dexamethasone at a concentration of 
20 µg/mL or 20 µM AC-YVAD-CHO treatments were used as controls. Cells were further incubated 
with LPS (Sigma, Saint-Louis, MO, USA) (at a final concentration of 1 µg/mL) for 3 h and then with 
5 µM ATP (Invitrogen/Thermofisher, Waltham, MA, USA) for additional 1 h. The caspase-1 activity 
was measured using the Caspase-Glo 1 Inflammasome Assay (Promega Co., Madison, WI, USA) 
according to the manufacturer’s instructions. The 24-well plate containing treated cells was removed 
from the incubator and 50 µL of the supernatant in each well were transferred to the corresponding 
well of a new white 96-well plate. An aliquot of 50 µL of the Caspase-Glo 1 reagent was then added 
to each well and gently mixed on a plate shaker at 300 rpm for 30 s. The mixture was then incubated 
for 1 h at room temperature before measuring the luminescence on a Berthold Technologies 
luminometer. 
4.5. THP-1-Derived Macrophage Treatment and Measurement of IL-1β 
The culture supernatant of stimulated the THP-1 macrophage was used for the measurement of 
the cleaved form of IL-1β. The concentration of IL-1β in the culture supernatant was measured using 
a human IL-1β ELISA kit (Invivogen/Thermofisher, Waltham, MA, USA) according to the 
manufacturer’s instructions. 
4.6. RAW264.7 Cell Treatment and Measurement of IL-6 Cytokine Production 
In all experiments, RAW264.7 cells were sub-cultured in a 24-well plate and incubated for 24 h 
at 37 °C and 5% CO2 to acclimate before treatment. They were then pretreated with test compounds, 
at indicated concentrations, for 3 h prior to 18 h stimulation with 1 µg/mL LPS. Cell-free supernatants 
were harvested and stored at −70 °C until analysis. The concentration of IL-6 in the culture 
supernatant was measured using an ELISA kit (BD Biosciences, Franklin Lakes, NJ, USA) according 
to the manufacturer’s instructions.  
4.7. Pyroptosis Inhibition Assay 
The evaluation of pyroptosis inhibition was done using the LDH-GloTM Cytotoxicity Assay 
(Promega Co. Madison, WI, USA). Briefly, THP-1 cells were cultured for 2 days in 96-well plates to a 
density of 5 × 104 cells/well in the presence of 10 nM PMA at 37 °C in a humidified 5% CO2 incubator. 
PMA-supplemented medium was then discarded and macrophages were pretreated with fresh 
medium containing fractions at different concentrations for 1 h. Dexamethasone at a concentration of 
20 µg/mL or 20 µM AC-YVAD-CHO treatments were used as controls. Cells were further incubated 
with LPS (Sigma, Saint-Louis, MO, USA) (at a final concentration of 1 µg/mL) for 3 h and then with 
5 µM ATP (Invitrogen/Thermofisher, Waltham, MA, USA) for additional 1 h. Then, 2 μL of 10% 
Triton X-100 was added to 100 μL of Vehicle-treated Cells Control for 5 min before collecting the 
samples for LDH detection. Supernatants were harvested and 20-fold diluted in the LDH storage 
buffer and kept at –70 °C until analysis. The LDH activity was measured using the LDH-Glo TM 
Cytotoxicity Assay (Promega Co., Madison, WI, USA) according to the manufacturer’s instructions. 
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The % Cytotoxicity = 100 × (Experimental LDH Release − Medium Background)/(Triton X-100 LDH 
Release Control − Medium Background). 
4.8. Immunoblotting Analysis 
For Western blot analysis, THP-1 cells (5 × 105 cells/well) were differentiated in a 12-well plate 
by 10 nM PMA for 2 days and then treated as stated above. Cells were washed with 600 µL of an ice-
cold PBS, and directly lysed with a reporter lysis buffer (Promega) and then centrifuged at 11,000 
rpm (round per minute) for 15 min at 4 °C. The supernatants were kept at −70 °C until analysis. The 
protein quantitation in the supernatant was quantified by the Bradford assay. An equivalent amount 
(15 µg of protein) of each sample was separated by sodium dodecyl sulfate polyacrylamide gel 
electrophoresis (SDS-PAGE) and electro-transferred onto Nitrocellulose membranes. The membranes 
were immunoblotted by anti-ProIL-1b (Cell signaling Technology, Danvers, MA, USA) or anti-Pro 
caspase-1 (abcam) according to the manufacturer’s instructions. Membranes were then stripped, 
reprobed with anti-β-Actin antibodies (Cell signaling Technology) and exposed again to detect the 
internal β-Actin standard. Immunoblots were visualized using a chemiluminescence Odyssey 
Imaging System (Odyssey®  Fc, Bad Homburg, Germany). To scan and quantify the immunoblots, we 
used the Image Studio Lite Ver 5.2 software (Li-Cor Biotechnology-GmbH, Bad Homburg, Germany). 
4.9. Data Presentation and Statistical Analysis 
Each test was done in triplicates and all the experiments were reproduced at least two times 
independently. For each ELISA experiment, the amount of IL-1β or IL-6 produced was considered as 
100% and the remaining treatments was calculated as (Treatment/LPS) × 100. The results are 
presented as the mean ± SD from two or three independent experiments (n = 3), each done in triplicate. 
Data were analyzed using GraphPad Prism 5 and Statistical Analysis Data expressed as the mean ± 
standard deviation. Comparisons of data between groups were performed by one-way ANOVA 
followed by Benforroni’s multiple comparison test. The p-values less than 0.05 were considered to be 
statistically significant. 
5. Conclusions 
Considering the importance of inflammasome components in the severity of respiratory diseases 
in general and in asthma in particular, our preliminary results at the molecular and functional levels 
suggest that H. noldeae and/or its constituents may play a role in the management of asthma and other 
respiratory diseases if the ex vivo results obtained can be reproduced in vivo. Additional purification 
and characterization of ER2.4 and ER2.7 fractions are of prime interest for our future study. 
Supplementary Materials: Supplementary materials are available online. Table S1: The 1H-NMR chemical shifts 
for the 3 purified compounds from H. noldeae. Figure S1: 1H–NMR spectrum of Quercetin-3-O-glucoside 
(isoquercetin). Figure S2: 13C spectrum of Quercetin-3-O-glucoside (isoquercetin) (DMSO-d6, 500 MHz). Figure 
S3: 1H, 13C-HMBC of Quercetin-3-O-Glucoside (isoquercetin) (DMSO-d6, 500 MHz). Figure S4: Effect of different 
H. noldeae’s constituents on the THP-1 cell viability. Figure S5: Effect of different H. noldeae constituents on the 
RAW264.7 cell viability. Figure S6: Crude extract and the ethylacetate fraction as well as the caffeic acid and 
semi-purified fractions (ER 2.4 and ER 2.7), thereof exhibited significant inhibition of pyroptosis in THP-1 
derived macrophages. 
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